Cargando...

Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia

GSK3α has been identified as a new target in the treatment of acute myeloid leukemia (AML). However, most GSK3 inhibitors lack specificity for GSK3α over GSK3β and other kinases. We have previously shown in lung cancer cells that GSK3α and to a lesser extent GSK3β are inhibited by the advanced clini...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Sci Rep
Main Authors: Kuenzi, Brent M., Remsing Rix, Lily L., Kinose, Fumi, Kroeger, Jodi L., Lancet, Jeffrey E., Padron, Eric, Rix, Uwe
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group UK 2019
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6345777/
https://ncbi.nlm.nih.gov/pubmed/30679640
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-018-37174-6
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!